{"pmid":32395897,"title":"Recent progress on the diagnosis of 2019 Novel Coronavirus.","text":["Recent progress on the diagnosis of 2019 Novel Coronavirus.","Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Therefore, convenient, timely, and accurate detection of SARS-CoV-2 is urgently needed. Here, we review the types, characteristics, and shortcomings of various detection methods, as well as perspectives for the SARS-CoV-2 diagnosis. Clinically, nucleic acid-based methods are sensitive but prone to false positive. The antibody-based method has slightly lower sensitivity but higher accuracy. Therefore, it is suggested to combine the two methods to improve the detection accuracy of COVID-19.","Transbound Emerg Dis","Li, Chun","Ren, Linzhu","32395897"],"abstract":["Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Therefore, convenient, timely, and accurate detection of SARS-CoV-2 is urgently needed. Here, we review the types, characteristics, and shortcomings of various detection methods, as well as perspectives for the SARS-CoV-2 diagnosis. Clinically, nucleic acid-based methods are sensitive but prone to false positive. The antibody-based method has slightly lower sensitivity but higher accuracy. Therefore, it is suggested to combine the two methods to improve the detection accuracy of COVID-19."],"journal":"Transbound Emerg Dis","authors":["Li, Chun","Ren, Linzhu"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395897","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/tbed.13620","keywords":["antibody","clustered regularly interspaced short palindromic repeats (crispr)","corona virus disease 2019 (covid-19)","detection","sars-cov-2)","severe acute respiratory syndrome coronavirus 2 (2019 novel coronavirus","real-time rt-pcr","reverse transcription loop-mediated isothermal amplification (rt-lamp)"],"topics":["Diagnosis"],"weight":1,"_version_":1666627827780288512,"score":9.490897,"similar":[{"pmid":32283141,"pmcid":"PMC7195339","title":"Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","text":["Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.","J Infect","Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong","32283141"],"abstract":["An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application."],"journal":"J Infect","authors":["Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283141","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.051","keywords":["colloidal gold-based","covid-19","immunochromatographic strip","real-time rt-pcr","sars-cov-2","serology"],"locations":["Wuhan","China","ICG strip"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491462877186,"score":179.42168},{"pmid":32353857,"title":"Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature.","text":["Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature.","COVID-19 has brought death and disease to large parts of the world. Governments must deploy strategies to screen the population and subsequently isolate the suspect cases. Diagnostic testing is critical for epidemiological surveillance, but the accuracy (sensitivity and specificity) and clinical utility (impact on health outcomes) of the current diagnostic methods used for SARS-CoV-2 detection are not known. I ran a quick search in PubMed/MEDLINE to find studies on laboratory diagnostic tests and rapid viral diagnosis. After running the search strategies, I found 47 eligible articles that I discuss in this review, commenting on test characteristics and limitations. I did not find any papers that report on the clinical utility of the tests currently used for COVID-19 detection, meaning that we are fighting a battle without proper knowledge of the proportion of false negatives that current testing is resulting in. This shortcoming should not be overlooked as it might hamper national efforts to contain the pandemic through testing community-based suspect cases.","Medwave","Bachelet, Vivienne C","32353857"],"abstract":["COVID-19 has brought death and disease to large parts of the world. Governments must deploy strategies to screen the population and subsequently isolate the suspect cases. Diagnostic testing is critical for epidemiological surveillance, but the accuracy (sensitivity and specificity) and clinical utility (impact on health outcomes) of the current diagnostic methods used for SARS-CoV-2 detection are not known. I ran a quick search in PubMed/MEDLINE to find studies on laboratory diagnostic tests and rapid viral diagnosis. After running the search strategies, I found 47 eligible articles that I discuss in this review, commenting on test characteristics and limitations. I did not find any papers that report on the clinical utility of the tests currently used for COVID-19 detection, meaning that we are fighting a battle without proper knowledge of the proportion of false negatives that current testing is resulting in. This shortcoming should not be overlooked as it might hamper national efforts to contain the pandemic through testing community-based suspect cases."],"journal":"Medwave","authors":["Bachelet, Vivienne C"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353857","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.5867/medwave.2020.03.7891","keywords":["diagnosis","sars-cov-2","testing","covid-19"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495699124224,"score":170.51324},{"pmid":32198501,"pmcid":"PMC7184472","title":"Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).","text":["Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).","BACKGROUND: Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Current method of detection involves qPCR-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. METHODS: The host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. Total 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but had typical manifestation). The diagnostic value of IgM was evaluated in this cohort. RESULTS: The median duration of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%). CONCLUSIONS: Humoral response to SARS-CoV-2 can aid to the diagnosis of COVID-19, including subclinical cases.","Clin Infect Dis","Guo, Li","Ren, Lili","Yang, Siyuan","Xiao, Meng","Chang, De","Yang, Fan","Dela Cruz, Charles S","Wang, Yingying","Wu, Chao","Xiao, Yan","Zhang, Lulu","Han, Lianlian","Dang, Shengyuan","Xu, Yan","Yang, Qiwen","Xu, Shengyong","Zhu, Huadong","Xu, Yingchun","Jin, Qi","Sharma, Lokesh","Wang, Linghang","Wang, Jianwei","32198501"],"abstract":["BACKGROUND: Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Current method of detection involves qPCR-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. METHODS: The host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. Total 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but had typical manifestation). The diagnostic value of IgM was evaluated in this cohort. RESULTS: The median duration of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%). CONCLUSIONS: Humoral response to SARS-CoV-2 can aid to the diagnosis of COVID-19, including subclinical cases."],"journal":"Clin Infect Dis","authors":["Guo, Li","Ren, Lili","Yang, Siyuan","Xiao, Meng","Chang, De","Yang, Fan","Dela Cruz, Charles S","Wang, Yingying","Wu, Chao","Xiao, Yan","Zhang, Lulu","Han, Lianlian","Dang, Shengyuan","Xu, Yan","Yang, Qiwen","Xu, Shengyong","Zhu, Huadong","Xu, Yingchun","Jin, Qi","Sharma, Lokesh","Wang, Linghang","Wang, Jianwei"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198501","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1093/cid/ciaa310","keywords":["covid-19","elisa","antibody","diagnosis","novel coronavirus"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490091339776,"score":158.13881},{"pmid":32431052,"title":"SARS-CoV-2 lgM/lgG antibody detection confirms the infection after three negative nucleic acid detection.","text":["SARS-CoV-2 lgM/lgG antibody detection confirms the infection after three negative nucleic acid detection.","An ongoing outbreak of viral pneumonia was caused by a novel coronavirus in China in 2019. By March 19, over 200 thousand confirmed cases of SARS-CoV-2 infection and over 9000 deaths have been reported throughout the world. For this infectious disease, nucleic acid detection is still the gold standard for pathogenic detection. However, nucleic acid detection takes a long time and has relatively high \"false negative\"; therefore, we need urgently a convenient and accurate detection method to make up for this deficiency. In this article, we will show such technical characteristics of lgM/lgG serum antibody detection, compared with nucleic acid detection.","J Cell Mol Med","Li, Hua","Pan, Jue","Su, Yi","Wang, Beili","Ge, Junbo","32431052"],"abstract":["An ongoing outbreak of viral pneumonia was caused by a novel coronavirus in China in 2019. By March 19, over 200 thousand confirmed cases of SARS-CoV-2 infection and over 9000 deaths have been reported throughout the world. For this infectious disease, nucleic acid detection is still the gold standard for pathogenic detection. However, nucleic acid detection takes a long time and has relatively high \"false negative\"; therefore, we need urgently a convenient and accurate detection method to make up for this deficiency. In this article, we will show such technical characteristics of lgM/lgG serum antibody detection, compared with nucleic acid detection."],"journal":"J Cell Mol Med","authors":["Li, Hua","Pan, Jue","Su, Yi","Wang, Beili","Ge, Junbo"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431052","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jcmm.15275","keywords":["sars-cov-2","lgm/lgg antibody detection","novel coronavirus"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1667342288208003075,"score":155.8797},{"pmid":32104917,"title":"Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.","text":["Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.","The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (severe acute respiratory syndrome coronavirus [SARS-Cov-2]) nucleic acid real-time polymerase chain reaction (PCR) test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false-negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify a large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay that can detect immunoglobulin M (IgM) and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at eight different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories.","J Med Virol","Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng","32104917"],"abstract":["The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (severe acute respiratory syndrome coronavirus [SARS-Cov-2]) nucleic acid real-time polymerase chain reaction (PCR) test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false-negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify a large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay that can detect immunoglobulin M (IgM) and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at eight different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories."],"journal":"J Med Virol","authors":["Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104917","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25727","keywords":["covid-19","sars-cov-2 virus infection","fingerstick blood","lateral flow immunoassay","point-of-care testing","rapid igm-igg combined test"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492879503361,"score":148.25694}]}